PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced the promotion of Michael Holfinger, Ph.D., to vice president, manufacturing and CMC development. Dr. Holfinger, who has more than two decades of experience in global manufacturing services for pharmaceutical and biotechnology companies, joined Affymax in 2006 as director, process development and manufacturing.
“During his tenure at Affymax, Mike has shown impressive leadership skills and made significant contributions to our process and manufacturing development program for OMONTYS,” said John Orwin, chief executive officer of Affymax. “Looking ahead, his proven track record of overseeing complex commercial production at a global level and his intimate familiarity with the manufacturing process we have developed with our partner, Takeda, will be essential as we increase commercial production.”
Prior to joining Affymax, Dr. Holfinger held multiple positions at Pfizer, including most recently as senior manager in the API support team where he was responsible for change management, project management and technical support activities necessary to ensure an economical uninterrupted commercial supply of pharmaceutical ingredients for various products. Prior to Pfizer, Dr. Holfinger held multiple positions within the chemical process research and development group at Pharmacia Corporation, where he was responsible for implementation of commercial processes for the manufacturing of chemical intermediates and active pharmaceutical ingredients. From 1997-2004, he was a course instructor at the Pharmaceutical Education & Research Institute. He earned his Ph.D. in chemical engineering from the University of Wisconsin-Madison and received a dual B.S. degree in applied science, paper science, and engineering and chemistry at Miami University.
About Affymax, Inc.
Affymax, Inc. is a biopharmaceutical company based in Palo Alto, California. Affymax's mission is to discover, develop and deliver innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses.
The company's first marketed product, OMONTYS® (peginesatide) Injection, was approved by the U.S. Food and Drug Administration (FDA) in March 2012. For additional information, please visit www.affymax.com.